Evidence map›Paper›PMID 22292079›Full record

ArticlePloS one2012

The HIV1 protein Vpr acts to enhance constitutive DCAF1-dependent UNG2 turnover.

Xiaoyun Wen, Laurieann Casey Klockow, Michael Nekorchuk, Hamayun J Sharifi, Carlos M C de Noronha

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
2.4field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 41 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. The emerging role for Cullin 4 family of E3 ligases in tumorigenesis.Biochimica et biophysica acta. Reviews on cancer · 2019
    Review
  12. HIV-1 Vpr hijacks EDD-DYRK2-DDB1The Journal of biological chemistry · 2018
    Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Xiaoyun WenCenter for Immunology and Microbial Disease, Albany Medical College, Albany, New York, United States of America.
Laurieann Casey Klockow
Michael Nekorchuk
Hamayun J Sharifi
Carlos M C de Noronha
Albany Medical Center Hospital · US

Funding

Vpr as a Mediator Proteasomal DegradationR01AI073178 · NIAID · ALBANY MEDICAL COLLEGE · PI DE NORONHA, CARLOS M · 2007 to 2010
$1.4M
NIAID NIH HHS 5R01AI073178NIAID NIH HHS R01 AI073178
6 · The paper itself

Abstract

backgroundThe HIV1 protein Vpr assembles with and acts through an ubiquitin ligase complex that includes DDB1 and cullin 4 (CRL4) to cause G2 cell cycle arrest and to promote degradation of both uracil DNA glycosylase 2 (UNG2) and single-strand selective mono-functional uracil DNA glycosylase 1 (SMUG1). DCAF1, an adaptor protein, is required for Vpr-mediated G2 arrest through the ubiquitin ligase complex. In work described here, we used UNG2 as a model substrate to study how Vpr acts through the ubiquitin ligase complex. We examined whether DCAF1 is essential for Vpr-mediated degradation of UNG2 and SMUG1. We further investigated whether Vpr is required for recruiting substrates to the ubiquitin ligase or acts to enhance its function and whether this parallels Vpr-mediated G2 arrest. METHODOLOGY/PRINCIPAL

findingsWe found that DCAF1 plays an important role in Vpr-independent UNG2 and SMUG1 depletion. UNG2 assembled with the ubiquitin ligase complex in the absence of Vpr, but Vpr enhanced this interaction. Further, Vpr-mediated enhancement of UNG2 degradation correlated with low Vpr expression levels. Vpr concentrations exceeding a threshold blocked UNG2 depletion and enhanced its accumulation in the cell nucleus. A similar dose-dependent trend was seen for Vpr-mediated cell cycle arrest. CONCLUSIONS/SIGNIFICANCE: This work identifies UNG2 and SMUG1 as novel targets for CRL4(DCAF1)-mediated degradation. It further shows that Vpr enhances rather than enables the interaction between UNG2 and the ubiquitin ligase. Vpr augments CRL4(DCAF1)-mediated UNG2 degradation at low concentrations but antagonizes it at high concentrations, allowing nuclear accumulation of UNG2. Further, the protein that is targeted to cause G2 arrest behaves much like UNG2. Our findings provide the basis for determining whether the CRL4(DCAF1) complex is alone responsible for cell cycle-dependent UNG2 turnover and will also aid in establishing conditions necessary for the identification of additional targets of Vpr-enhanced degradation.

Indexed as

Active Transport, Cell NucleusCarrier ProteinsCell NucleusDNA GlycosylasesGene Expression RegulationHEK293 CellsHIV-1HIV InfectionsHumansModels, BiologicalProtein Processing, Post-TranslationalProtein Serine-Threonine KinasesProteolysisTissue DistributionUbiquitin-Protein LigasesUp-RegulationCarrier ProteinsCCNO protein, humanDCAF1 protein, humanDNA GlycosylasesProtein Serine-Threonine KinasesUbiquitin-Protein Ligasesvpr Gene Products, Human Immunodeficiency Virus

Identifiers

PMID22292079
PMCPMC3265533
OpenAlexW1984614142

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.